Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Double vaccine against Human Immunodeficient virus

23.07.2007
A vaccine against HIV infections is the most reliable way to stop the AIDS epidemic. A lot of researchers in various countries have been working for more than 20 years to cope with this task. However, the vaccine development is complicated by the fact that human immunodeficiency virus is very changeable, it is able to “hide” from the immune system and causes heavy immunopathologies.

The Novosibirsk researchers have developed a vaccine that is able to cause both humoral and cellular immunity, it means that under the influence of this vaccine, activated cells of the immune system will both form virus antibodies and devour the cells infected by the virus.

The vaccine per se is an artificial virus-like particle. Its capsule consists of the TBI (T- and B cell epitopes containing immunogen) protein constructed by the researchers, the TBI protein being combined with the polyglucin protein. This protein contains 9 participants stimulating different cells of the immune system – both the ones that produce antibodies and the ones that devour the newcomer. The DNA coding the TCI (T-cell immunogen) protein is contained inside the protein coat. The protein contains more than 80 HIV proteins fragments selected in the optimal way, which should activate the immune system.

The researchers have selected only conservative fragments, i.e. the ones that remain constant in the course of all major changes of HIV-1 and will certainly be noticed by the immunize organism. As a matter of fact, the coat and the filling of the particle represent independent vaccines, which cause specific cellular and humoral immune response. In the assembled form, the combiHiVvac vaccine is a particle 40 to 100 nanometers in diameter, approaching in size to the HIV-1 virus.

The antibodies, which are formed by immunized mice under the action of vaccine, recognize the real HIV-1 proteins and neutralize the virus. This was shown by the experiments on the cell culture infected by the virus and processed by mice’s antibodies. Preclinical trial findings allow to hope that the combiHIVvac vaccine will fight efficiently even against modified HIV-1 variants.

The new vaccine is nontoxic. Its single injection to mice even in the fivefold dose does not cause derangements to the organs, and repeated injections reinforce inflammatory processes in the liver, but only in the case if the liver is already out of order. The combiHIVvac vaccine does not cause autoimmune diseases or anaphylactic reactions, it does not weaken the organism’s tolerance to infections either.

The scientists emphasize that as the combiHIVvac vaccine not only stimulates antibody production but also destroys the cells infected by the virus, this vaccine can be considered not only a prophylactic one but also as a therapeutic one. In the Novosibirsk researchers’ opinion, the vaccine they developed is ready for clinical trials.

Nadezda Markina | alfa
Further information:
http://www.informnauka.ru

More articles from Health and Medicine:

nachricht Speed data for the brain’s navigation system
06.12.2016 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Simple processing technique could cut cost of organic PV and wearable electronics

06.12.2016 | Materials Sciences

3-D printed kidney phantoms aid nuclear medicine dosing calibration

06.12.2016 | Medical Engineering

Robot on demand: Mobile machining of aircraft components with high precision

06.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>